THYROCARE Thyrocare Technologies Q3 FY26 results (Oct–Dec 2025) and concall
Thyrocare Technologies reported a strong Q3 FY26, with consolidated revenue growing 18% YoY to INR 196 crores, driven by robust performance across its pathology, franchisee, and partnerships segments. Profitability saw significant improvement, with consolidated normalized EBITDA margin at 32% and PAT increasing by 47%. The company continued its focus on operational excellence, expanding its network and achieving a Six Sigma quality benchmark, while also investing in specialty diagnostics and international expansion.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 18.1%, net profit up 47.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 177 | 166 | 187 | 193 | 217 +23% | 196 +18% |
| EBITDA | 48 | 42 | 57 | 58 | 71 +48% | 58 +38% |
| Net profit | 26 | 19 | 22 | 38 | 48 +85% | 28 +47% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
